首页 /药靶模型 /免疫治疗 /Co-Stimulatory /CD40/CHO

CD40/CHO

CBP74034

询 价
索取Protocol
产品描述
产品数据库
I. Background
CD40, a TNF receptor superfamily member, was initially identified on B lymphocytes. However, other cell types such as monocytes, basophils, dendritic cells, endothelial cells, and epithelial cells have been found to express CD40. High levels of CD40 have also been detected in numerous human cancers, including HCT116, a colon cancer epithelial cell line. Interaction with CD40 ligand (CD40L, CD154) on CD4+ T helper lymphocytes triggers the expression of intercellular adhesion molecule (ICAM) and other pro-inflammatory cytokines. CD40:CD40L signaling simultaneously increases activation of antigen-specific T cells. CD40 also activates NF-κB-dependent signaling in response to lipopolysaccharide (LPS) found on Gram negative bacterial pathogens. Agonistic CD40 monoclonal antibodies have been shown to activate antigen presenting cells (APC), promote anti-tumor T-cell responses, and to foster cytotoxic myeloid cells, suggesting a potential mechanism to control cancer in the absence of T-cell immunity.
 
II. Description

Recombinant CHO cell line expressing full length human CD40 (Tumor necrosis factor receptor superfamily member 5; TNFRSF5), Genbank Accession No. NP_001241.1.

 
III. Introduction
Host Cell: CHO
Expressed gene: CD40
Stability: 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)
Freeze Medium: 90% FBS+10% DMSO
Culture Medium:

F12k+10%FBS+5ug/ml puromycin

Storage: Liquid nitrogen
Application(s): Binding Assay,FACS
 
IV. Description of Host Cell Line
Organism: Cricetulus griseus, hamster, Chinese
Tissue: Ovary
Disease: Hamster Chinase ovary
Morphology: Epitheloid cell
Growth Properties: Adherent
 
Ⅴ. Representative Data

Figure 1. Recombinant CHO cell line expressing full length human CD40.


药靶模型联系方式: 华东销售经理:18240630236 全国销售经理:18066071954
诊断标准品联系方式: 华东销售经理:15000320447 华北销售经理:18131625521 华南销售经理:13484295986 华中&西南销售经理:13871580511 全国销售经理:13484295986

扫二维码

立即提交